Manama: A telephone conversation took place between His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, and Dr. Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals. During the call, significant medical achievements and future collaborations were discussed.
According to Bahrain News Agency, His Royal Highness highlighted Bahrain's recent medical milestone wherein the Kingdom successfully treated the world's first sickle cell disease patient outside the United States using Casgevy (exagamglogene autotemcel). This CRISPR-based gene-editing therapy was accomplished through advanced bone marrow transplantation technology.
His Royal Highness reaffirmed the importance of strengthening Bahrain's partnership with Vertex Pharmaceuticals, aiming to explore future opportunities that will bolster the Kingdom's health sector. This partnership is expected to enhance Bahrain's position as a leader in scientific and medical advancements.
Prince Salman emphasized Bahrain's commitment to collaborating with leading international specialized medical institutions, ensuring the Kingdom remains at the forefront of scientific progress. He stressed the importance of integrating cutting-edge treatments into the healthcare and rehabilitation services available to Bahrainis, underscoring this as a top priority for the Kingdom's health initiatives.